← All trials
NCT05343819
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 12, 2022
- Primary completion
- Nov 29, 2022
- Completion date
- Nov 29, 2022
- First posted
- Apr 25, 2022
- Last posted
- Dec 19, 2022
- Enrollment
- 16
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Aptarion Biotech AGLead sponsor
- Nuvisan Pharma ServicesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.